“Ozempic teeth” is not a diagnosis, and no trial has measured it. What exists is a set of oral effects reported consistently enough to take seriously, with no study yet attaching a rate to any of them. That is a different kind of gap from the one in the pooled serious adverse events, where the trials counted and the total was small.
What is actually reported
A narrative review of semaglutide and the mouth drew on clinical trials, pharmacovigilance analyses, observational studies, case reports and laboratory work [1]. Dry mouth — xerostomia or hyposalivation — is the effect it found reported most consistently. The review states that rates vary across studies and does not combine them. That is the same unpooled shape this site described in two meta-analyses built on the same six trials.
Alongside dry mouth it lists altered taste, dry throat, reduced sensation in the mouth, bad breath, frothy saliva and more dental caries. Reporting systems show signals for dry mouth and taste change, and case series confirm reduced saliva, though a reporting signal measures what was reported rather than how often it happens.
A second review, covering the oral and maxillofacial region specifically, adds reflux, nasopharyngitis and taste disturbance to the same list [2]. Its authors ask clinicians to keep these drugs in the differential diagnosis, because the effects overlap with conditions that have entirely different causes.
Why teeth, when the drug does not touch them
| What happens | Why it follows | What it does to teeth |
|---|---|---|
| Less saliva | Nausea, eating and drinking less, slower gastric emptying | Saliva buffers acid and clears sugar; less of it raises caries risk |
| Reflux | Delayed gastric emptying pushes acid upward | Acid reaches enamel directly |
| Altered taste | Reported directly with the drug | Can change what and how often someone eats |
The first review is careful about the order of events: dry mouth often arrives secondary to gastrointestinal symptoms rather than from the drug acting on salivary glands directly. That matters for what a reader can do about it. A mouth that is dry because someone is drinking less is a different problem from a gland that has stopped working.
One study points the other way
A 2026 review of the oral microbiome in obstructive sleep apnea argues that these drugs introduce competing influences [3]. Untreated sleep apnea drives mouth breathing, salivary drying and acid challenge on its own. So a drug that reduces apnea severity may improve the oral environment, even while its salivary effects push the other way.
That review is a synthesis of mechanisms rather than a measurement of outcomes, so it does not settle the question. It does mean a blanket claim in either direction is unsupported. The apnea evidence itself is in what happened across every apnea subgroup.
What nobody has measured
No randomized trial has counted cavities in people taking these drugs. No study reports what share of users develop dry mouth, or how long it lasts, or whether it resolves when the dose stops climbing. Those are not gaps this site can close by reading harder; they are measurements nobody has taken.
One of the reviews also records that these drugs promote a gaunt facial appearance, which is the observation behind a much larger volume of searching than the dental one. That deserves its own page and does not yet have one here.
For a reader currently on one of these drugs, the practical implication is narrow. Dryness and reflux are both worth raising at a dental appointment, as medication effects rather than as unrelated symptoms. What a seller will tell you about any of this is covered in whether disclosure is a trait of the seller.